Research programme: ocular disorder therapeutics - KalVista/ Gadea Grupo Farmaceutico/University College Dublin/Universidad de Valladolid/RenaSci

Drug Profile

Research programme: ocular disorder therapeutics - KalVista/ Gadea Grupo Farmaceutico/University College Dublin/Universidad de Valladolid/RenaSci

Alternative Names: 3D-NET

Latest Information Update: 23 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gadea Grupo Farmaceutico; KalVista Pharmaceuticals; RenaSci; Universidad de Valladolid; University College Dublin
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Eye-Disorders

Most Recent Events

  • 17 Jul 2015 Gadea Grupo Farmaceutico has been acquired by AMRI
  • 25 Sep 2013 The 3D-NET project receives a Marie Curie Industry-Academia Pathways and Partnerships grant from the European Commission to develop treatments for Ocular disorders
  • 25 Sep 2013 Early research in Eye disorders in Ireland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top